Experimental Treatment Shows Promise Against Triple-Negative Breast Cancer

Jan 6, 2019 | Breast Cancer, Cancer Research

As reported in Science Daily, by simultaneously tackling two mechanisms for cancer’s growth, an experimental therapy reduced the spread of triple-negative breast cancer in a study conducted in mice.bg protein and blocks two of the main pathways by which breast cancer cells can grow and migrate out of the primary tumor to spread to other organs in the body. The study was published in the journal Cancer Cell on Jan. 3.

“People have tried to block the spread of this form of cancer but attempts so far have failed because if you try one approach, the cancer cells compensate by finding a way to escape,” said Yibin Kang, the Warner-Lambert/Parke-Davis Professor of Molecular Biology at Princeton University, associate director for consortium research at the Rutgers Cancer Institute of New Jersey, and senior author on the study. “With this innovative approach, the treatment blocks both pathways at the same time. It is like having one stone that kills two birds.”

Triple-negative breast cancer is a highly aggressive form of cancer that occurs in 12 to 17 percent of all breast cancer cases. It gets its name from the lack of three prominent biological targets — the estrogen receptor (ER), the progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) — that are used to find and kill cancer cells.

Lead Research/investigator

Yibin Kang

0 Comments

Pin It on Pinterest